Telaglenastat plus cabozantinib in patients with metastatic kidney cancer
Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinoma
MiT family translocation renal cell carcinoma is a rare and [...]
Weight loss with cabozantinib use in patients with metastatic kidney cancer
This recent study looked at the effects of cabozantinib on [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer
Preliminary results from the COSMIC-313 clinical trial have ben released. [...]
Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
Cabozantinib for collecting duct carcinoma
Collecting duct carcinoma is a rare and aggressive form of [...]
Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer
This phase 1 clinical trial looked at the safety, tolerability, [...]
ASCO GU 2022: Neoadjuvant cabozantinib clinically active in kidney cancer
Results from a phase 2 study were presented at the [...]
